TOP PICK
Medtronic Inc

Medical technology demand growing.
Surgery demand growing after the end of Covid-19.
Current share price a good buying opportunity.
Large exposure to Asia market.
Aging population also a good factor. 

biotechnology / pharmaceutical
SELL ON STRENGTH
Medtronic Inc

Ugly chart. Street opinion is a blend of Buy and Hold at these levels. She waits to see a trend reversal before getting in. Fundamentally, 9/10. Diverse portfolio, likes the positioning. Healthcare is great before a recession, but better names out there. Ride it out until you can break even.

(Analysts’ price target is $94.00)
biotechnology / pharmaceutical
BUY
Medtronic Inc

It reports next week. A great value name. Medtronic has been focusing on organic growth. 

biotechnology / pharmaceutical
COMMENT
Medtronic Inc

It is a great company which is well diversified. It had problems with some heart devices that didn't work out well. He prefers Stryker  which is in the field of joint replacement, is well managed, less risky and a better value.

biotechnology / pharmaceutical
Unspecified
Medtronic Inc

He has owned it for 20 years. It beat in the last quarter and pays a good dividend. However there are names that are a little better such as J&J and Danaher.

biotechnology / pharmaceutical
WATCH
Medtronic Inc

A medical tech powerhouse, up 15% this year. The FDA approved their diabetes-management device, which triggered upgrades. Shares have struggled in past years, but is showing life. It reports Thursday, which he will watch. It could turnaround.

biotechnology / pharmaceutical
TOP PICK
Medtronic Inc

After a rough 18 months it is now a turn-around story. It is in the growth area of global medical devices. The headwinds have been supply chain issues, Covid, and inflation. It missed earnings in all four quarters last year. It has a growing dividend of 3 1/2 %.  
Buy 13   Hold 16   Sell 2

(Analysts’ price target is $89.74)
biotechnology / pharmaceutical
BUY
Medtronic Inc
A generative AI play

They specialize in surgical robots and tools, implants and patient monitoring systems. Are partnering with Nvidia to build an AI platform for medical devices, like the recently approved first AI-enabled colonoscopy tool that could detected cancer. This gives MDT new hope, new life.

biotechnology / pharmaceutical
DON'T BUY
Medtronic Inc

Covid turned everything on its head. Surgeries have been put off. Revenues, cashflow, and earnings have gone flat. We need the catalyst of more procedures and loosening of the hospital system, he doesn't know when this will happen. A fine company, but it's hard to predict when reality might change.

biotechnology / pharmaceutical
TOP PICK
Medtronic Inc
46 years of raising the dividend and will continue. Shares have fallen off recently though. Balance sheet is strong and has a record of tuck-in acquisitions. Buy and hold a long time. (Analysts’ price target is $90.54)
biotechnology / pharmaceutical
WATCH
Medtronic Inc
Likes healthcare. Not performing as well as peers. 200-day MA is falling, price is below. Not executing well. 15x forward earnings for a weak 5% growth rate. Wait to see if it shows better technical strength. Don't buy it just for the yield of 3.4%.
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Medtronic Inc
(A Top Pick Aug 09/22, Down 15.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MDT has triggered its stop at $79. To remain disciplined, we recommend covering the position at this time.
biotechnology / pharmaceutical
BUY
Medtronic Inc
Aging demographics help. It's selling below 2x below its 5-year average, and has a 6% operating cash flow yield. He expects solid earnings next week.
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Medtronic Inc
Stockchase Research Editor: Michael O'Reilly This $124 billion market cap manufacturer of medical devices ranging from insulin pumps to pacemakers is the world's largest in its class. It has raised dividends for 46 consecutive years. It has been buying back stock while maintaining steady cash reserves and trades at just 2.4x earnings. The resumption in surgical procedures as the pandemic calms down is expected to lead to substantial uplift in EPS going forward. We recommend setting a stop loss at $79, looking to achieve $117 -- upside over 25%. Yield 2.92% (Analysts’ price target is $117.13)
biotechnology / pharmaceutical
PAST TOP PICK
Medtronic Inc
(A Top Pick Jan 15/21, Down 7%) Company has increased dividend for almost 50 years, however needs a good acquisition to grow. Stock price is low which creates a buying opportunity. Will continue to buy and hold.
biotechnology / pharmaceutical
Showing 1 to 15 of 109 entries

Medtronic Inc(MDT-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 5

Stockchase rating for Medtronic Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Medtronic Inc(MDT-N) Frequently Asked Questions

What is Medtronic Inc stock symbol?

Medtronic Inc is a American stock, trading under the symbol MDT-N on the New York Stock Exchange (MDT). It is usually referred to as NYSE:MDT or MDT-N

Is Medtronic Inc a buy or a sell?

In the last year, 5 stock analysts published opinions about MDT-N. 3 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Medtronic Inc.

Is Medtronic Inc a good investment or a top pick?

Medtronic Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Medtronic Inc.

Why is Medtronic Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Medtronic Inc worth watching?

5 stock analysts on Stockchase covered Medtronic Inc In the last year. It is a trending stock that is worth watching.

What is Medtronic Inc stock price?

On 2023-09-28, Medtronic Inc (MDT-N) stock closed at a price of $78.69.